# A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

> **NCT06929299** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu BioJeTay Biotechnology Co., Ltd.** · enrollment: 56 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** STSA-1301 subcutaneous injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06929299
- **Lead sponsor:** Jiangsu BioJeTay Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06929299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06929299, "A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06929299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*